Sep 28, 2015MAJESTIC Trial Data Support Strong Safety Profile with Low Target Lesion Revascularization Rate
New 12-month clinical trial outcomes assessing the safety and performance of the Boston Scientific (NYSE: BSX) Eluvia™ Drug-Eluting Vascular Stent System reflect a primary patency rate1 of more...
Sep 26, 2015New clinical trial data assessing the Boston Scientific Lotus™ Valve System continue to support strong performance and safety profile
Results from clinical trials evaluating the Boston Scientific (NYSE: BSX) Lotus™ Valve System continue to show this advanced transcatheter aortic valve implantation (TAVI) therapy delivers...
Sep 10, 2015System includes first directional lead with current steering and expanded programming flexibility
Boston Scientific (NYSE: BSX) has received CE Mark for the Vercise™ Primary Cell (PC) Deep Brain Stimulation (DBS) System. The Vercise PC System is intended to provide precise neural targeting...
Aug 31, 2015Subcutaneous defibrillators now recommended by the 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
Boston Scientific welcomes the updated ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death announced during ESC Congress 2015, the...
Aug 24, 2015
Boston Scientific Corporation (NYSE: BSX) has received CE Mark on magnetic resonance imaging (MRI) conditional labeling for the current family of EL (Extended Longevity) and MINI implantable...